Drugs / Nefazodone
Nefazodone
also known as
BMY 13754 · Dutonin · MJ 13,754-1 · Nefazodona · Nefazodone hcl · NEFAZODONE HYDROCHLORIDE · NSC-760344 · Serzone
Small molecule targets HTR2A, HTR2C, SLC6A2, SLC6A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | SERZONE | — | 2009-03-13 | fda.gov ↗ |
| Approved | US (FDA) | SERZONE | — | 1994-12-22 | fda.gov ↗ |
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00249509 | Sep 2000 → Sep 2004 | hallucinogen abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000286 | Dec 1996 → Dec 2001 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00000293 | Jan 1999 → Dec 2001 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00231348 | ? → Apr 2000 | social phobia | Emory University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00015210 Comparator | Feb 1997 → May 1999 | cocaine dependence | Boston Medical Center | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2003-09-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Nefazodone HCl Tablets 50 mg, 100 mg, 150 mg, 200 mg and 250 mg tevapharm.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nefazodone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000286 ↗ |
| Known as | BMY 13754 | ChEMBL registry synonym — accepted as the source's own label CHEMBL623 ↗ |
| Known as | Dutonin | ChEMBL registry synonym — accepted as the source's own label CHEMBL623 ↗ |
| Known as | MJ 13,754-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL623 ↗ |
| Known as | Nefazodona | ChEMBL registry synonym — accepted as the source's own label CHEMBL623 ↗ |
| Known as | Nefazodone hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL623 ↗ |
| Known as | NEFAZODONE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL623 ↗ |
| Known as | NSC-760344 | ChEMBL registry synonym — accepted as the source's own label CHEMBL623 ↗ |
| Known as | Serzone | ChEMBL registry synonym — accepted as the source's own label CHEMBL623 ↗ |
| Action | Inhibit | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL623 ↗4“Serotonin 2c (5-HT2c) receptor antagonist” CHEMBL623 ↗ “Norepinephrine transporter inhibitor” CHEMBL623 ↗ “5HT2 receptor antagonist nefazadone” NCT00231348 ↗ “Serotonin transporter inhibitor” CHEMBL623 ↗ |
| Modality | Small molecule | — CHEMBL623 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL623 ↗ |
| Target | HTR2C | “Serotonin 2c (5-HT2c) receptor antagonist” CHEMBL623 ↗ |
| Target | SLC6A2 | “Norepinephrine transporter inhibitor” CHEMBL623 ↗ |
| Target | SLC6A4 | “Serotonin transporter inhibitor” CHEMBL623 ↗ |